Pancreatic cancer is devastating primarily because of when it is found. Only 15-20% of patients are diagnosed at a stage when curative surgery is still possible. The rest present with disease that has already spread beyond the pancreas or invaded critical blood vessels — situations where surgery cannot help and long-term survival is rare. Incidence is rising, and the disease is expected to become one of the most common causes of cancer death in Western countries within years.
The fundamental problem is biological: pancreatic cancer has a long preclinical phase during which it grows silently without detectable symptoms. When symptoms finally appear — abdominal pain, weight loss, or jaundice — they typically signal advanced or metastatic disease. The window for curative intervention passes before most patients know to seek it.
A small but identifiable group of people carry dramatically elevated lifetime risk due to hereditary genetic syndromes. Hereditary pancreatitis carries a 25-40% lifetime risk; Peutz-Jeghers syndrome carries 11-32%; familial atypical mole melanoma syndrome carries 17%. These high-risk groups are now offered surveillance with endoscopic ultrasound (EUS) and MRI, though even in these populations, the 'number needed to screen' to find one high-risk lesion is 135 people.
Population-wide screening is not currently recommended because the overall low incidence of pancreatic cancer means even a highly accurate test would generate many false positives, leading to unnecessary biopsies, anxiety, and harm that outweighs benefit. The challenge is to identify which members of the general population have elevated enough risk to make screening worthwhile.
One of the most promising strategies for early detection focuses on a counterintuitive observation: pancreatic cancer itself can cause diabetes by destroying insulin-producing cells. People aged over 50 who develop new-onset diabetes — particularly when accompanied by unexplained weight loss — have a significantly elevated risk of harboring an early pancreatic cancer.
A risk prediction model called ENPAC (Enriching New-Onset Diabetes for Pancreatic Cancer) combines age, changes in blood glucose, and weight change to stratify risk. A score of 3 or higher on this model identified patients with 80% sensitivity and specificity for developing PDAC — a promising tool for identifying which newly-diabetic patients warrant pancreatic imaging.
Radiomics — the extraction of quantitative features from medical images using AI — is emerging as a tool to detect subtle changes in the pancreas before a mass becomes visible on conventional imaging. One study reported that radiomics with machine learning could detect PDAC up to two years before clinical diagnosis using existing CT scan data, suggesting that important tumor signatures are present in images that radiologists currently read as normal.
In patients with pancreatic cysts (IPMNs), radiomics AI tools demonstrated superiority over conventional imaging models for distinguishing which cysts need surgery. Critically, the AI correctly identified true negatives (patients who could safely avoid surgery) and caught true positives that conventional imaging missed — directly reducing unnecessary operations while catching dangerous lesions.
Liquid biopsies — tests that detect cancer signals in blood, urine, or saliva — represent the most ambitious frontier for early pancreatic cancer detection. These tests analyze circulating tumor DNA, microRNAs, extracellular vesicles, and metabolic markers shed by cancers into body fluids. Some metabolomics studies have found that branched-chain amino acid levels in blood are elevated more than two years before a pancreatic cancer diagnosis.
Despite promising early results, no liquid biopsy test yet meets the clinical standard needed for population screening. Standardization, validation in large prospective cohorts, and regulatory approval all remain ahead. The emerging strategy is a 'Define-Enrich-Find' framework: define who is at risk, enrich surveillance in that population, and find disease using the most sensitive tools available for that enriched group.